CC BY-NC-ND 4.0 · J Lab Physicians 2022; 14(02): 169-174
DOI: 10.1055/s-0041-1735583
Original Article

A Microbiological Study of Acinetobacter calcoaceticus baumannii with Special Reference to Multidrug Resistance

1   Department of Microbiology, Sikkim Manipal Institute of Medical Sciences, Gangtok, Sikkim, India
Dechen Chomu Tsering
1   Department of Microbiology, Sikkim Manipal Institute of Medical Sciences, Gangtok, Sikkim, India
Dipmala Das
2   Department of Microbiology, IQ City Medical College and Hospital, Durgapur, West Bengal, India
› Author Affiliations


Introduction The outbreak of Acinetobacter calcoaceticus baumannii (ACB) is mainly reported to be a notorious pathogens at health-care settings. It is the major problem on the health-care system with high morbidity and mortality rates because of the broad range of antibiotic resistance and lack of understanding the mechanism of developing new antibiotic resistance rapidly. It emphasizes the importance of local surveillance in describing or understanding and predicting microbial resistance patterns so that there will be limited use of antibiotics by developing strategies to control the extensive use of antimicrobial chemotherapy in clinical environment, which is still considered as one of the factors in the emergence of multidrug resistance microorganisms.

Objectives The study aims to detect the occurrence rate of ACB infections from various clinical samples, identify the resistance levels to different groups of antimicrobial agents, and the occurrence rate of multidrug resistant (MDR) ACB clinical isolates from a tertiary hospital in Durgapur, West Bengal, India.

Material and Methods The study was performed in the Department of Microbiology of the IQ City Medical College and Hospital, Durgapur, West Bengal, India, for the 24 months duration, that is, from January 1, 2018 to December 31, 2019. Altogether 15,800 clinical samples consisting of endotracheal tube aspirates, sputum, pus, blood, catheter tips, urine, tissue, and other body fluids were studied. ACB from clinical samples were identified by its characteristic colonies (nonlactose fermenting, glistening, small mucoid colonies), Gram-staining pattern (Gram-negative coccobacillus), and standard biochemical reactions. It was further confirmed in the Department of Microbiology of the Healthworld Hospital, Durgapur, West Bengal, India, by Vitek2 compact system (bioMerieux, Inc., Durham, North Carolina, United States). Antibiotic susceptibility testing was performed using automated broth microdilutions by Vitek2 compact system (bioMerieux, Inc.) and Kirby-Bauer disk diffusion test on Mueller-Hinton Agar (HiMedia).

Results Nonrepetitive 289 ACB were isolated from various clinical samples. A total of 277 (96%) isolates of ACB were MDR strains.

ConclusionACB was mostly isolated from the intensive care unit department and was found to be the most MDR type in the tertiary care hospital by this study.

Source(s) of Support


Authors' Contributions

L.L.A.: Literature search, review of literature, manuscript preparation, concept and design of the study, data collection, statistically analyzed and interpreted, prepared first draft of manuscript, and critical review of study proposal.

D.C.T.: Scientific advisor, critical review of study proposal, and helped in preparing first draft of manuscript.

D.D.: Scientific advisor, critical review of study proposal, and data collection.

Publication History

Article published online:
22 September 2021

© 2021. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

  • References

  • 1 Centers for Disease Control. Overview of Drug-resistant Acinetobacter infections in healthcare settings. Centers for Disease Control and Prevention. Accessed February 18, 2017 at:
  • 2 Manchanda V, Sanchaita S, Singh N. Multidrug resistant acinetobacter. J Glob Infect Dis 2010; 2 (03) 291-304
  • 3 Corbella X, Pujol M, Ayats J. et al. Relevance of digestive tract colonization in the epidemiology of nosocomial infections due to multiresistant Acinetobacter baumannii. Clin Infect Dis 1996; 23 (02) 329-334
  • 4 Abbo A, Navon-Venezia S, Hammer-Muntz O, Krichali T, Siegman-Igra Y, Carmeli Y. Multidrug-resistant Acinetobacter baumannii. Emerg Infect Dis 2005; 11 (01) 22-29
  • 5 Hsueh P-R, Teng L-J, Chen C-Y. et al. Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan. Emerg Infect Dis 2002; 8 (08) 827-832
  • 6 Fernández-Cuenca F, Martínez-Martínez L, Conejo MC, Ayala JA, Perea EJ, Pascual A. Relationship between beta-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii. J Antimicrob Chemother 2003; 51 (03) 565-574
  • 7 Rice LB. Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2006; 43 (Suppl. 02) S100-S105
  • 8 Bergogne-Bérézin E. The increasing significance of outbreaks of Acinetobacter spp.: the need for control and new agents. J Hosp Infect 1995; 30 (Suppl): 441-452
  • 9 Go ES, Urban C, Burns J. et al. Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 1994; 344 (8933): 1329-1332
  • 10 Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 2007; 5 (12) 939-951
  • 11 Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21 (03) 538-582
  • 12 Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 2006; 12 (09) 826-836
  • 13 Wareham DW, Bean DC, Khanna P. et al. Bloodstream infection due to Acinetobacter spp: epidemiology, risk factors and impact of multi-drug resistance. Eur J Clin Microbiol Infect Dis 2008; 27 (07) 607-612
  • 14 Souli M, Kontopidou FV, Koratzanis E. et al. In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals. Antimicrob Agents Chemother 2006; 50 (09) 3166-3169
  • 15 Clinical and Laboratory Standards Institute (CLSI).. Performance Standards for Antimicrobial Susceptibility Testing (M100S). 28th ed.. Wayne, PA: CLSI; 2018
  • 16 Talukdar A, Hodiwala AB, Sharma R. Amicrobiological study of Acinetobacter baumannii with special reference to multi-drug resistance. Int J Curr Microbiol Appl Sci 2018; 7 (02) 2319-7706
  • 17 Khan ID, Basu A, Kiran S, Trivedi S, Pandit P, Chattoraj A. Device-Associated Healthcare-Associated Infections (DA-HAI) and the caveat of multiresistance in a multidisciplinary intensive care unit. Med J Armed Forces India 2017; 73 (03) 222-231
  • 18 Banerjee T, Mishra A, Das A, Sharma S, Barman H, Yadav G. High prevalence and endemicity of multidrug resistant Acinetobacter spp. in intensive care unit of a tertiary care hospital, Varanasi, India. J Pathogens 2018; 2018: 9129083
  • 19 Seifert H, Stefanik D, Wisplinghoff H. Comparative in vitro activities of tigecycline and 11 other antimicrobial agents against 215 epidemiologically defined multidrug-resistant Acinetobacter baumannii isolates. J Antimicrob Chemother 2006; 58 (05) 1099-1100
  • 20 Mehrad B, Clark NM, Zhanel GG, Lynch III JP. Antimicrobial resistance in hospital-acquired Gram-negative bacterial infections. Chest 2015; 147 (05) 1413-1421